Results 31 to 40 of about 3,475,545 (379)

Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity

JAMA Network Open, 2023
Key Points Question Can plasma biomarker analytes be used in a low-resource community to improve clinical accuracy in diagnosing Alzheimer disease (AD)?
L. Honig, M. Kang, Annie J. Lee, D. Reyes-Dumeyer, A. Piriz, Belisa Soriano, Yahaira Franco, Zoraida Dominguez Coronado, Patricia Recio, Diones Rivera Mejía, Martin A. Medrano, R. Lantigua, A. Teich, J. Dage, R. Mayeux   +14 more
semanticscholar   +1 more source

Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma

Liver Cancer, 2021
Introduction: Cabozantinib, an inhibitor of MET, AXL, and VEGF receptors, significantly improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients with previously treated advanced hepatocellular carcinoma (HCC). In this
Lorenza Rimassa, Robin Kate Kelley, Tim Meyer, Baek-Yeol Ryoo, Philippe Merle, Joong-Won Park, Jean-Frederic Blanc, Ho Yeong Lim, Albert Tran, Yi-Wah Chan, Paul McAdam, Evelyn Wang, Ann-Lii Cheng, Anthony B. El-Khoueiry, Ghassan K. Abou-Alfa   +14 more
doaj   +1 more source

Longitudinal changes in Alzheimer's‐related plasma biomarkers and brain amyloid

Alzheimer's & Dementia, 2023
Understanding longitudinal plasma biomarker trajectories relative to brain amyloid changes can help devise Alzheimer's progression assessment strategies.
Murat Bilgel, Y. An, K. Walker, A. Moghekar, N. Ashton, P. Kac, T. Karikari, K. Blennow, H. Zetterberg, B. Jedynak, M. Thambisetty, L. Ferrucci, S. Resnick   +12 more
semanticscholar   +1 more source

Biomarker analyses of clinical outcomes in patients with advanced hepatocellular carcinoma treated with Sorafenib with or without Erlotinib in the SEARCH Trial [PDF]

, 2016
Purpose: Sorafenib is the current standard therapy for advanced HCC, but validated biomarkers predicting clinical outcomes are lacking. This study aimed to identify biomarkers predicting prognosis and/or response to sorafenib, with or without erlotinib,
Evans, T.R. Jeffrey, Gane, Edward, Jeffers, Michael, Kang, Yoon-Koo, Meinhardt, Gerold, Peña, Carol E.A., Rosmorduc, Olivier, Ross, Paul, Santoro, Armando, Vogel, Arndt, Zhu, Andrew X.   +10 more
core   +1 more source

Plasma biomarkers for neuronal ceroid lipofuscinosis [PDF]

The FEBS Journal, 2015
The neuronal ceroid lipofuscinoses (NCLs) are a group of neurodegenerative genetic diseases that primarily affect children and have no known cure. A unified clinical rating scale for the juvenile form of NCL has been developed, although it has not been validated in other subtypes and does not give a true measure of the pathophysiological changes ...
Krystal L. Weber, David A. Pearce, Ryan D. Geraets, Samantha L. Hersrud, Chun-Hung Chan   +4 more
openaire   +3 more sources

Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon [PDF]

, 2017
Background and aims Increased levels of chemokine interferon-gamma (IFN-γ)-inducible protein-10 (CXCL10), soluble CD163 (sCD163) and soluble CD14 (sCD14) have been reported in HCV infection.
Furlan, Caterina, Iannetta, Marco, Lichtner, Miriam, Marocco, Raffaella, Mascia, Claudia, Mastroianni, Claudio Maria, Mengoni, Fabio, Pozzetto, Irene, Rossi, Raffaella, Savinelli, Stefano, Tieghi, Tiziana, Vita, Serena, Vullo, Vincenzo, Zuccalà, Paola   +13 more
core   +11 more sources

Uncovering Biologically Coherent Peripheral Signatures of Health and Risk for Alzheimer’s Disease in the Aging Brain

Frontiers in Aging Neuroscience, 2018
Brain aging is a multifaceted process that remains poorly understood. Despite significant advances in technology, progress toward identifying reliable risk factors for suboptimal brain health requires realistically complex analytic methods to explain ...
Brandalyn C. Riedel, Madelaine Daianu, Greg Ver Steeg, Adam Mezher, Lauren E. Salminen, Aram Galstyan, Paul M. Thompson, Paul M. Thompson, Alzheimer’s Disease Neuroimaging Initiative   +8 more
doaj   +1 more source

Impact of pre‐analytical sample handling factors on plasma biomarkers of Alzheimer's disease

Journal of Neurochemistry, 2023
An unmet need exists for reliable plasma biomarkers of amyloid pathology, in the clinical laboratory setting, to streamline diagnosis of Alzheimer's disease (AD).
C. Kurz, Laura Stöckl, Isabelle Schrurs, I. Suridjan, Selim Üstün Gürsel, T. Bittner, Alexander Jethwa, R. Perneczky   +7 more
semanticscholar   +1 more source

Association of Systemic Inflammation With Retinal Vascular Caliber in Patients With AIDS. [PDF]

, 2019
PurposeTo evaluate relationships among retinal vascular caliber and biomarkers of systemic inflammation in patients with AIDS.MethodsA total of 454 participants with AIDS had retinal vascular caliber (central retinal artery equivalent and central retinal
Cheu, Ryan, Danis, Ronald P, Hunt, Peter W, Jabs, Douglas A, Jones, Norman, Klatt, Nichole R, Milush, Jeffrey M, Pak, Jeong Won, Trang, Garrett, Van Natta, Mark L   +9 more
core   +1 more source

Objective subtle cognitive decline and plasma phosphorylated tau181: Early markers of Alzheimer's disease‐related declines

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 2021
Introduction Objectively‐defined subtle cognitive decline (Obj‐SCD) and plasma phosphorylated‐tau181 (p‐tau181) are promising early Alzheimer's disease (AD) markers.
Kelsey R. Thomas, Katherine J. Bangen, Emily C. Edmonds, Alexandra J. Weigand, Kayla S. Walker, Mark W. Bondi, Douglas R. Galasko, for the Alzheimer's Disease Neuroimaging Initiative   +7 more
doaj   +1 more source